Puma Biotechnology
pharmaceutical company
PBYI Nasdaq
ISIN US74587V1070 SEC CIK 1401667
Follow Puma Biotechnology
Weekly email: filings, results
Revenue, last quarter
$55.1M
+1.1% vs same quarter last year
Net income
$6M
−32.7% vs same quarter last year
EPS, diluted
$0.11
−35.3% vs same quarter last year
Operating cash flow
$14.6M
+50.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $228.4M | $31.1M |
| FY24 | $230.5M | $30.3M |
| FY23 | $235.6M | $21.6M |
| FY22 | $228M | $2K |
| FY21 | $253.2M | - |
| FY20 | $225.1M | −$60M |
| FY19 | $272.3M | −$75.6M |
| FY18 | $251M | −$113.6M |
| FY17 | $27.7M | −$292M |
| FY16 | - | −$276M |
| FY15 | - | −$239.3M |
| FY14 | - | −$142M |
| FY13 | - | −$54.7M |
| FY12 | - | −$74.4M |
| FY11 | - | −$10.2M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 74.5% | 16.3% | 13.6% |
| FY24 | 72.1% | 13.4% | 13.1% |
| FY23 | 73.4% | 13.9% | 9.2% |
| FY22 | 75.8% | 10.4% | 0% |
| FY21 | 74.8% | 0.5% | - |
| FY20 | 82.5% | −13.5% | −26.7% |
| FY19 | 86.5% | −14.3% | −27.8% |
| FY18 | 86.2% | −37.7% | −45.3% |
| FY17 | 79.9% | −1056.1% | −1054.6% |
| FY16 | - | - | - |
| FY15 | - | - | - |
| FY14 | - | - | - |
| FY13 | - | - | - |
| FY12 | - | - | - |
| FY11 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $41.7M |
| FY24 | $38.9M |
| FY23 | $26.9M |
| FY22 | −$15.8M |
| FY21 | $20.7M |
| FY20 | $727K |
| FY19 | $22.1M |
| FY18 | −$24.5M |
| FY17 | −$172.9M |
| FY16 | −$146M |
| FY15 | −$155.5M |
| FY14 | −$78.3M |
| FY13 | −$55.7M |
| FY12 | - |
| FY11 | −$2.1M |
- Puma Biotechnology
- Healthcare median
Show the numbers
| Year | Puma Biotechnology | Healthcare median |
|---|---|---|
| FY25 | 13.6% | −30.6% |
| FY24 | 13.1% | −47% |
| FY23 | 9.2% | −58% |
| FY22 | 0% | −80.4% |
| FY21 | - | −71.8% |
| FY20 | −26.7% | −62.2% |
| FY19 | −27.8% | −46.2% |
| FY18 | −45.3% | −49.6% |
| FY17 | −1054.6% | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |